Get the Stockscreener App
16.59
4.76%
-0.83
Pre-market:
16.50
-0.09
-0.54%
Beta Bionics Inc stock is traded at $16.59, with a volume of 957.71K.
It is down -4.76% in the last 24 hours and up +1.16% over the past month.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
See More
Previous Close:
$17.42
Open:
$17.6
24h Volume:
957.71K
Relative Volume:
0.84
Market Cap:
$746.38M
Revenue:
$110.24M
Net Income/Loss:
$-66.44M
P/E Ratio:
-10.98
EPS:
-1.5111
Net Cash Flow:
$-61.12M
1W Performance:
-16.72%
1M Performance:
+1.16%
6M Performance:
+51.23%
1Y Performance:
-33.29%
1-Day Range:
$16.50
$17.95
1-Week Range:
$16.50
$19.97
52-Week Range:
$8.80
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
Name
Beta Bionics Inc
Sector
Industry
Phone
949-427-7785
Address
11 HUGHES, IRVINE
Compare BBNX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
16.59 | 746.38M | 110.24M | -66.44M | -61.12M | -1.5111 |
ABT
Abbott Laboratories
|
103.36 | 178.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.19B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 103.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 62.46B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 50.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | UBS | Buy |
| Jan-27-26 | Initiated | TD Cowen | Hold |
| Jan-09-26 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-21-25 | Resumed | Stifel | Buy |
| Oct-01-25 | Upgrade | Goldman | Neutral → Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| Jun-12-25 | Initiated | Lake Street | Buy |
| May-30-25 | Initiated | Goldman | Neutral |
| May-30-25 | Initiated | Wolfe Research | Outperform |
| Feb-24-25 | Initiated | BofA Securities | Buy |
| Feb-24-25 | Initiated | Lake Street | Buy |
| Feb-24-25 | Initiated | Leerink Partners | Outperform |
| Feb-24-25 | Initiated | Piper Sandler | Overweight |
| Feb-24-25 | Initiated | Stifel | Buy |
| Feb-20-25 | Initiated | Ladenburg Thalmann | Neutral |
| Feb-20-25 | Initiated | Robert W. Baird | Neutral |
View All
Beta Bionics Inc Stock (BBNX) Latest News
Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSS - GlobeNewswire
Beta Bionics (BBNX) CCO sells 36,870 shares under preset plan - Stock Titan
Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm Before Lead Plaintiff Deadline on November 3, 2026 - NewMediaWire
Kaplan Fox Reminds Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to a Securities Class Action DeadlineContact the Firm Before November 3, 2026 - NewMediaWire
Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
Faruqi & Faruqi, LLP Urges Beta Bionics (BBNX) Investors to Seek - The National Law Review
BBNX Investor Alert: Johnson Fistel Encourages Beta - GlobeNewswire
BETA BIONICS, INC. INVESTORS WITH LOSSES HAVE UNTIL - GlobeNewswire
BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities LawsuitContact SueWallSt - PR Newswire
Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights - FinancialContent
Beta Bionics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Insider plans to sell about $779K in Beta Bionics (NASDAQ: BBNX) stock - Stock Titan
BBNX Class Action Notice: Beta Bionics Sued for Securities Fraud After Allegedly Misleading Investors about the Safety of its Medical Device – Investors Urged to Contact BFA Law - Business Wire
Beta Bionics faces a securities lawsuit after F... - Pluang
BBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class ActionContact Levi & Korsinsky - PR Newswire
Berger Montague PC Investigating Claims on Behalf of Investors in Beta Bionics, Inc. (BBNX) After Class Action Filing - marketscreener.com
BETA BIONICS, INC. (BBNX) INVESTOR ALERT Investors With Large Losses in Beta Bionics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - Procurement Magazine
BBNX INVESTOR ALERT: Securities Class Action Filed Against Beta Bionics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
BBNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Beta Bionics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff Deadline - lincolnjournal.com
BBNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026 - Bluefield Daily Telegraph
Class action lawsuit filed against Beta Bionics over faulty insulin pump issues. - Pluang
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit - PR Newswire
BETA BIONICS, INC. (BBNX) INVESTOR ALERT Investors With - GlobeNewswire
BETA BIONICS, INC. (BBNX) INVESTOR ALERT Investors With Large Losses in Beta Bionics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewswire Inc.
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - Business Wire
BBNX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta ... - pmg-ky3.com
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files - GlobeNewswire
Class action lawsuit alleges Beta Bionics misled investors on FDA safety findings for its insulin pump. - Pluang
BBNX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Beta Bionics Inc. - PR Newswire
BBNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Beta Bionics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Beta Bionics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – BBNX - FinancialContent
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders - Supply Chain Digital
Beta bionics CEO Sean Saint sells $113,258 in company stock By Investing.com - Investing.com India
Have Beta Bionics Insiders Been Selling Stock? - simplywall.st
Beta Bionics CFO Stephen Feider sells $127,579 in stock By Investing.com - Investing.com South Africa
Beta Bionics Faces Securities Class Action Lawsuit - stl.news
Beta bionics CEO Sean Saint sells $113,258 in company stock - Investing.com
Investor Alert: Robbins LLP Informs Investors of the Beta Bionics Inc. Class Action Lawsuit - FinancialContent
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit - FinancialContent
Beta Bionics CPO Mike Mensinger sells $83,619 in stock By Investing.com - Investing.com South Africa
Beta Bionics CEO Sean Saint Executes Sale of 5,641 Shares via 10b5-1 Trading Plan - Kalkine Media
Beta Bionics (BBNX) CEO sells 5,641 shares under preset plan - Stock Titan
Beta Bionics CCO Hopman Mark Disposes of 5,327 Shares at $19.11 Each (NASDAQ: BBNX) - Kalkine Media
Beta Bionics CEO Saint Sean Offloads 16,867 Shares at $19.11 Each (NASDAQ: BBNX) - Kalkine Media
Beta bionics CCO Mark Hopman sells $101,815 in stock By Investing.com - Investing.com South Africa
Beta Bionics CEO Sean Saint disposes of 5,641 common shares for $113,261.01 - Bitget
Beta Bionics CMO Russell sells $80,676 in company stock By Investing.com - Investing.com South Africa
President & CEO Sean Saint sells $322,380 in Beta Bionics stock - Investing.com Australia
Beta Bionics Inc Stock (BBNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.29%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):